Edwards Lifesciences is a heavily covered, NYSE-listed medical device maker, and recent analyst action skews clearly bullish. S&P Global data aggregates roughly 30 analyst price targets spanning $84 to $110, producing an overall mean near $101. Because that figure sits almost exactly at the 10% threshold relative to the latest price, the $105 target used here is calculated from only the most recent, verifiable targets above the current price, which cluster between roughly $100 and $110.
Recent revisions illustrate the shift in sentiment. In October 2026, BTIG, UBS, Barclays, Citi, and RBC Capital each carried $110 price targets, while TD Cowen stood at $104, Jefferies at $105, and Leerink Partners and Piper Sandler near $101. Earlier in 2026, J.P. Morgan upgraded the stock to Overweight, and UBS lifted its rating to Buy. The more cautious end of the range, near $84 to $87, reflects analysts wary of valuation and slower growth in certain segments.
At a closing price near $92.01 on Oct. 30, 2026, moving to $105 would require a rise of roughly 14%, a substantial move for a large-cap healthcare name. The shares rallied through late October toward the mid-$90s, near their recent 52-week high zone, before pulling back about 2.6% on Oct. 30. For the target to be reached, the stock would need to clear its prior high near $95 and hold above it, converting that resistance into support.
Edwards remains a leader in structural heart disease, anchored by its transcatheter aortic valve replacement (TAVR) franchise and a growing transcatheter mitral and tricuspid (TMTT) pipeline. Management has raised guidance, and analysts have cited favorable TAVR reimbursement and policy updates as growth tailwinds. A series of recent Buy and Overweight ratings, along with higher price targets, signal improving expectations for revenue growth and market share. The JenaValve acquisition expands its position in tricuspid valve repair, a long-term growth opportunity if execution follows.
The clearest obstacle is valuation. Edwards trades at roughly 37 times earnings, above the roughly 30x average for the U.S. medical equipment peer group, leaving limited room for error if growth disappoints. Analysts also flag potential EPS (earnings per share) dilution from the JenaValve deal and tariff-related cost pressure. Competition in structural heart from large rivals such as Boston Scientific and Abbott remains intense, and any slowdown in TAVR procedure volumes or softer-than-expected guidance could trigger multiple compression.
The stock's recent high near $95 is the first meaningful resistance, with $105 then representing the next psychological milestone above that breakout zone. On the downside, $88 to $90 has served as a recurring support area during the October advance, with the broader 52-week range spanning from the low $70s to the mid-$90s. Holding above $90 would keep the near-term uptrend intact.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Investors should watch upcoming quarterly results and guidance, analyst target revisions, TAVR and TMTT procedure growth, progress on the JenaValve integration, tariff developments, and any shifts in the Federal Reserve interest-rate outlook that could affect premium-growth valuations.
AI Daily Buy/Sell Signals is an artificial-intelligence tool that continuously monitors thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a stock like Edwards Lifesciences, which sits near a technical resistance zone, such signals can help traders spot changing momentum and manage positions more efficiently. Traders exploring EW's outlook may find it a useful complement to fundamental research.
The $105 central target, derived from the mean of recent analyst targets above the current price, implies a roughly 14% advance from about $92. A genuinely bullish analyst camp, improved guidance, and structural heart leadership support the case, but a premium valuation and integration and competitive risks cut the other way. The wide $84-to-$110 range reflects genuine disagreement about how much growth is already priced in. Whether EW can reach $105 will depend most on sustained procedure growth and whether the stock can clear and hold its prior highs. No outcome is guaranteed, and the target is a reference point, not a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EW has been loosely correlated with ISRG. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if EW jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To EW | 1D Price Change % |
|---|---|---|
| EW | 100% | -0.67% |
| Health Services category (239 stocks) | 6% Poorly correlated | +0.37% |
| Medical/Nursing Services category (138 stocks) | 6% Poorly correlated | +0.85% |